Table 1

Baseline characteristics of study participants

CharacteristicsControl
n=251
n (%)
Stroke/TIA
n=461
n (%)
P value
Age, years (SD)70.5 (11.6)69.8 (12.5)0.45
Sex, female88 (35.1)195 (42.3)0.06
Stroke subtypes
 Large vessel atherosclerosis82 (17.8)
 Small vessel occlusion86 (18.7)
 Cryptogenic291 (63.1)
 Stroke of other determined aetiology2 (0.4)
Vascular risk factors
 Hypertension130 (51.8)294 (63.8)0.01
 Dyslipidaemia91 (36.3)209 (45.3)0.02
 Diabetes mellitus38 (15.1)113 (24.5)0.01
 Any smoking44 (17.5)118 (25.6)0.01
 Previous stroke/TIA0 (0)79 (17.1)<0.001
 Myocardial infarction40 (15.9)82 (17.8)0.53
 Peripheral vascular disease5 (2.0)26 (5.6)0.02
 Sleep apnoea14 (5.6)13 (2.8)0.07
 History of heart failure11 (4.4)25 (5.4)0.55
 CHA2DS2VASc score, median (IQR)2 (1–3)5 (4–5)<0.001
Medications
 Warfarin4 (1.6)4 (0.9)0.38
 Direct oral anticoagulant4 (1.6)1 (0.2)
 Antiplatelet therapy81 (32.3)165 (35.8)0.35
 Beta blocker48 (19.1)82 (17.8)0.66
 Ace inhibitor105 (41.8)224 (48.6)0.08
 Statin79 (31.5)187 (40.6)0.02
Premature atrial complexes
 PACs/24 hours, median (IQR)37 (13–115)62 (20–208)<0.01
 Longest atrial run, median (IQR)3 (0–7)3 (0–8)<0.01
 Atrial runs >3 beats, median (IQR)1 (0–2)1 (0–4)0.07
 ≥200 PACs/24 hours37 (14.7)118 (25.6)<0.001
 ≥20 beats in runs13 (5.2)27 (5.9)0.71
  • The data are presented as n (%), unless otherwise stated.

  • PACs, premature atrial complexes; TIA, transient ischaemic attack.